Cytopia targeting protein kinases
Wednesday, 18 June, 2008
Melbourne biotech Cytopia (ASX: CYT) is to present data from its study on FMS inhibitors at the Protein Kinase Targets oncology conference in Boston next week.
This will be the first formal disclosure of data from the study, in which a series of compounds discovered by Cytopia were found to inhibit the function of microphages, key cells in the immune system which also mediate inflammatory reactions.
One of the potential applications of the compounds is as a treatment of rheumatoid arthritis. The compounds are also showing potential as an inhibitor of the cells that cause bone osteolysis in advanced cancer sufferers.
Quitting smoking increases life expectancy even for seniors
Although the benefits of quitting smoking diminish with age, there are still substantial gains...
Stem cell transplants treat blindness in mini pigs
Scientists have successfully transplanted retinas made from stem cells into blind mini pigs,...
Sugary drinks raise cardiovascular disease risk, but occasional sweets don't
Although higher sugar intake raises your risk of certain cardiovascular diseases, consuming sweet...
